Iovance Biotherapeutics. has been granted a patent for methods to expand tumor infiltrating lymphocytes (TILs) in a closed system, enhancing their efficacy and metabolic health while reducing contamination and costs. The process includes gene-editing and involves multiple expansion steps without opening the system. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Iovance Biotherapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of June 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for expanding therapeutic tumor infiltrating lymphocytes (tils)
The patent US12031157B2 outlines a method for producing a therapeutic population of tumor infiltrating lymphocytes (TILs) from tumor fragments resected from patients. The process involves several key steps: first, tumor fragments are introduced into a closed system to generate a first population of TILs. This initial population undergoes a first expansion in a culture medium containing interleukin-2 (IL-2) and optionally OKT-3, lasting approximately 3-12 days. The second expansion occurs in a similar medium supplemented with antigen presenting cells (APCs) for an additional 7-12 days, resulting in a third population of TILs, which is characterized as therapeutic. Notably, the transitions between these steps occur without opening the system, ensuring a controlled environment throughout the process.
Additionally, the patent details the potential for gene-editing at various stages of TIL development, specifically targeting immune checkpoint genes to enhance therapeutic efficacy. The gene-editing can be performed on any of the TIL populations and aims to silence or reduce the expression of specific immune checkpoint genes, such as PD-1, CTLA-4, and LAG-3, among others. Techniques for gene-editing include the use of programmable nucleases, such as CRISPR or TALE systems, with the option to introduce mRNA encoding TALE nucleases via electroporation. The patent also mentions the possibility of cryopreserving the harvested therapeutic TILs, further extending their usability in clinical applications.
To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
